Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
Interv Neuroradiol. 2023 Dec;29(6):725-730. doi: 10.1177/15910199221110971. Epub 2022 Jun 26.
The optimal approach to the management of intracranial atherosclerotic disease (ICAD) at the time of mechanical thrombectomy (MT) for large vessel occlusion (LVO) remains controversial. The goal of this study is to characterize current practices concerning this challenging clinical situation in a survey of practicing neurointerventionalists.
An electronic questionnaire was sent to a cross-section of North American academic neurointerventionalists using publicly available contact information and departmental websites. Prior to analysis, responses were anonymized and categorized by region.
A total of 136/360 responses were recorded from the U.S. and Canada. The mean number of years of practicing as a neurointerventionalist among the respondents was 10.5 (± 6.2 years). ICAD was perceived as a causative factor during MT for LVO in 5-10% of thrombectomy cases. The most common first-line treatment approach for significant ICAD, assuming a TICI 2b or better reperfusion, was medical therapy (77.9% of respondents), followed by angioplasty + stent placement (8.8% of respondents). There were no significant differences in the first line treatment of ICAD in LVO between geographical regions (p = 0.815).
The approach to underlying ICAD in LVO varies widely; however, the majority of neurointerventionalists prefer medical therapy with DAPT as a first-line treatment approach. The current survey highlights the need for studies that better define the optimal timing and modality of treatment, along with an evidence-based framework for balancing the risks associated with these treatment approaches.
在机械取栓(MT)治疗大血管闭塞(LVO)时,针对颅内动脉粥样硬化性疾病(ICAD)的最佳处理方法仍存在争议。本研究的目的是通过对神经介入医师的调查,描述当前在这种具有挑战性的临床情况下的实践方法。
使用公开的联系方式和部门网站,向北美学术神经介入医师发送了一份电子问卷。在分析之前,对答复进行了匿名处理并按区域进行了分类。
从美国和加拿大共记录了 136/360 份答复。答复者作为神经介入医师的平均从业年限为 10.5(±6.2 年)。在 MT 治疗 LVO 中,有 5-10%的患者认为 ICAD 是一个致病因素。对于有意义的 ICAD,假设 TICI 2b 或更好的再灌注,最常见的一线治疗方法是药物治疗(77.9%的受访者),其次是血管成形术+支架置入术(8.8%的受访者)。在 LVO 中,不同地理区域之间的 ICAD 一线治疗方法没有显著差异(p=0.815)。
在 LVO 中,对基础 ICAD 的处理方法差异很大;然而,大多数神经介入医师更倾向于将 DAPT 作为一线治疗方法的药物治疗。目前的调查强调了需要进行更好地定义治疗时机和方式的研究,以及为平衡这些治疗方法相关风险制定循证框架的必要性。